The mineralocorticoid receptor antagonist did not reduce primary outcomes in the CLEAR SYNERGY trial, but there was a suggestion that it did prevent new or worsening heart failure.

New research found that the medication spironolactone, often prescribed for hypertension (high blood pressure), may reduce the risk of heart failure in people recovering from a heart attack.

Over 2 decades ago, the aldosterone antagonist eplerenone proved beneficial after MI complicated by left ventricular ...

Part 2 of this 7,000-patient trial suffered from discontinuations and low event rates: still, early MRAs did not impact CV ...